Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs

Table 5

Previous studies of nontype 1 ROP treatment.

Investigator	Time published	Country	Method	Cases	Treatment	Reasons of treatment^β
Gupta et al. [3]	2016	USA	Multicenter retrospective study	A total of 137 eyes treated, 13 eyes with nontype 1 ROP	Laser	Concerning structural changes, persistent ROP at an advanced PMA (41 w), vitreous hemorrhage, and active ROP with the fellow eye being treated for type 1 ROP
Liu et al. [5]	2019	USA	Multicenter retrospective study	A total of 1004 eyes, 126 eyes with nontype 1 ROP	Laser in 122 eyes and IVR^α in 4 eyes	Fellow eye with type 1 ROP, stage 3 ROP with preplus, and others: concerning structural changes in the retina; persistent stage 3 for ≥6 weeks without regression; stage 3 with no plus; stage 3, zone III with plus; logistical considerations; stage 2 disease.
Rajan et al. [11]	2020	India	Retrospective study	A total of 241 eyes treated, 33 eyes with nontype 1 ROP	Laser in 32 eyes, IVR^α in 1 eye	Structural changes, preplus disease, persistent stage 3 ROP that did not show any sign of regression for 6 weeks, and active ROP with the fellow eye being treated.
Koucheki et al. [12]	2020	Canada	Retrospective study	2,356 cases and 115 cases (172 eyes) with stage 3 ROP persisting ≥ PMA 40 w	Of 21 cases (33 eyes) treated by laser, 17 eyes with nontype 1 ROP	≥2 continuous clock hours of persistent stage 3 crossing the temporal horizontal midline and preplus

^αIVR, intravitreal injection of bevacizumab. ^βReasons of treatment were arranged in the descending order of proportion.